The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Impaired Endothelium-Dependent Vasodilatation in Subclinical Hypothyroidism: Beneficial Effect of Levothyroxine Therapy
Abstract
Subclinical hypothyroidism (sHT) is associated with enhanced cardiovascular risk. To test the hypothesis that patients with sHT are characterized by endothelial dysfunction and impaired nitric oxide (NO) availability, in 14 patients [serum cholesterol, 218 +/- 41 mg/dl (5.6 +/- 0.9 mM)] and 28 euthyroid subjects, subdivided into groups A and B [serum cholesterol, 170 +/- 19 mg/dl (4.4 +/- 0.5 mM) and 217 +/- 21 mg/dl (5.6 +/- 0.5 mM), respectively], we studied the forearm blood flow (strain-gauge plethysmography) response to intrabrachial acetylcholine, an endothelium-dependent vasodilator, at baseline and during infusion of N(G)-monomethyl-L-arginine (L-NMMA), a NO synthase inhibitor. Response to sodium nitroprusside and minimal forearm vascular resistances were also evaluated. In sHT patients, vasodilation to acetylcholine was reduced, compared with group B (+358 +/- 29% vs. +503 +/- 19%, P = 0.0003) and group A (663 +/- 65%, P = 0.02 vs. group B and P = 0.0002 vs. sHT). L-NMMA blunted the vasodilation to acetylcholine in groups A and B (49.1 +/- 6.3% and 42.7 +/- 5.5% maximal forearm blood flow reduction, respectively, P < 0.0001 vs. acetylcholine), whereas it was ineffective in sHT patients (12.8 +/- 2.5%). Response to sodium nitroprusside and minimal vascular resistances were similar. In sHT (n = 9) patients, 6 months of euthyroidism by levothyroxine replacement increased acetylcholine-vasodilation and restored L-NMMA inhibition. Patients with sHT are characterized by endothelial dysfunction resulting from a reduction in NO availability, an alteration partially independent of dyslipidemia and reversed by levothyroxine supplementation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both hyperlipidemia and thyroid antibodies are thought to reduce expression of endothelial nitric oxide synthase, thereby impairing vasodilation (15).”
From Thyroid Hormones and Cardiovascular Function and Diseases (2018) · cites this paper as [15]
Citations
Cites
Furchgott, R. F., & Zawadzki, J. V. (1980) · Nature · doi:10.1038/288373a0 · Cited by 12,064
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
Palmer, R. M. J., Ferrige, A. G., & Moncada, S. (1987) · Nature · doi:10.1038/327524a0 · Cited by 10,704 · cited 1×
“The most important vasodilator substance produced by the endothelium is nitric oxide (NO) (18, 19), derived from the conversion of l-arginine into citrulline via the activity of the enzyme NO-synthase (20).”
BackgroundVascular endothelial cells synthesize nitric oxide from L-arginine
Palmer, R. M. J., Ashton, D., & Moncada, S. (1988) · Nature · doi:10.1038/333664a0 · Cited by 4,786
The Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
Schächinger, V., Britten, M. B., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.101.16.1899 · Cited by 2,589
Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase
Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C. J., Reed, R. R., & Snyder, S. H. (1991) · Nature · doi:10.1038/351714a0 · Cited by 2,354
Long-Term Follow-Up of Patients With Mild Coronary Artery Disease and Endothelial Dysfunction
Suwaidi, J. M. S. A., Hamasaki, S., Higano, S. T., Nishimura, R. A., Holmes, D. R., & Lerman, A. (2000) · Circulation · doi:10.1161/01.cir.101.9.948 · Cited by 2,044
Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T., & Münzel, T. (2001) · Circulation · doi:10.1161/hc4601.099485 · Cited by 1,961
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man
Vallance, P., Collier, J., & Moncada, S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91013-1 · Cited by 1,590
The measurement of volume changes in human limbs
Whitney, R. J. (1953) · The Journal of Physiology · doi:10.1113/jphysiol.1953.sp004926 · Cited by 1,496
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355
Hak, A. E., Pols, H. A. P., Visser, T. J., Drexhage, H. A., Hofman, A., & Witteman, J. C. M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-4-200002150-00004 · Cited by 1,336
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.
Creager, M. A., Cooke, J. P., Mendelsohn, M. E., Gallagher, S. J., Coleman, S. M., Loscalzo, J., & Dzau, V. J. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114688 · Cited by 1,017
Taddei, S., Virdis, A., Ghiadoni, L., Magagna, A., & Salvetti, A. (1998) · Circulation · doi:10.1161/01.cir.97.22.2222 · Cited by 757
CARTER, V. B. (1951) · PubMed · Cited by 740
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686
Fichtlscherer, S., Rosenberger, G., Walter, D. H., Breuer, S., Dimmeler, S., & Zeiher, A. M. (2000) · Circulation · doi:10.1161/01.cir.102.9.1000 · Cited by 665 · cited 1×
“In this regard, all the patients had thyroiditis; and therefore, a possible concomitant effect of inflammation and autoimmunity should be not overlooked, because inflammatory states are associated with endothelial dysfunction (35).”
Background19. Department of Internal Medicine
Katô/Chang (1999) · University of California Press eBooks · doi:10.1525/9780520923393-021 · Cited by 647
The Endothelium: Modulator of Cardiovascular Function
Lüscher, T. F., & Vanhoutte, P. M. (2020) · CRC Press eBooks · doi:10.1201/9780429281808 · Cited by 523
IMMUNOREACTIVE α-INTERFERON IN INSULIN-SECRETING β CELLS IN TYPE 1 DIABETES MELLITUS
Foulis, A. K., Farquharson, M. A., & Meager, A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91128-7 · Cited by 454
Assessment and treatment of endothelial dysfunction in humans
Anderson, T. J. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00259-4 · Cited by 443
L-Thyroxine Therapy in Subclinical Hypothyroidism: A Double-Blind, Placebo-Controlled Trial
COOPER, D. S., HALPERN, R., WOOD, L. C., LEVIN, A. A., & RIDGWAY, E. C. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-1-18 · Cited by 423
Schultz, K.-D., Schultz, K., & Schultz, G. (1977) · Nature · doi:10.1038/265750a0 · Cited by 420
Meier, C., Staub, J.-J., Roth, C.-B., Guglielmetti, M., Kunz, M., Miserez, A. R., Drewe, J., Huber, P., Herzog, R. F. K., & Müller-Stich, B. P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7973 · Cited by 397
Caraccio, N., Ferrannini, E., & Monzani, F. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8378 · Cited by 294
Thompson, P. L., Aylward, P. E., Federman, J., Harris, P., Hodge, R. L., Latt, N. K. Z., Pitt, A., Thomson, A. G., Tonkin, A. M., Byrne, A. C., et al. (1988) · The Lancet · Cited by 284
Lekakis, J. P., Papamichael, C. M., Alevizaki, M. K., Gd, P., MARAFELIA, P., Mantzos, J. D., Stamatelopoulos, S., & Koutras, D. A. (1997) · Thyroid · doi:10.1089/thy.1997.7.411 · Cited by 236
The Treatment of Subclinical Hypothyroidism Is Seldom Necessary
Chu, J. W., & Crapo, L. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7961 · Cited by 231
Subclinical hypothyroidism: neurobehavioral features and beneficial effect of l-thyroxine treatment
Monzani, F., Guerra, P., Caracciol, N., Pruneti, C. A., Puccil, E., Luisit, M., & Baschieri, L. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00186625 · Cited by 204
Surks, M. I., & Ocampo, E. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89462-4 · Cited by 192
Kugiyama, K., Doi, H., Motoyama, T., Soejima, H., Misumi, K., Kawano, H., Nakagawa, O., Yoshimura, M., Ogawa, H., Matsumura, T., et al. (1998) · Circulation · doi:10.1161/01.cir.97.25.2519 · Cited by 187
PRECLINICAL HYPOTHYROIDISM: A RISK FACTOR FOR CORONARY HEART-DISEASE*1
Bastenie, P. A. (1971) · The Lancet · doi:10.1016/s0140-6736(71)90947-0 · Cited by 152
Changes in Lipoprotein(a) Levels in Overt and Subclinical Hypothyroidism Before and During Treatment
Tzotzas, T., Krassas, G. E., Κωνσταντινίδης, Θ. Κ., & Bougoulia, M. (2000) · Thyroid · doi:10.1089/thy.2000.10.803 · Cited by 150
AUTOIMMUNE MECHANISMS IN HUMAN VASCULAR DISEASE
Mathews, J. D., Whittingham, S., & Mackay, I. R. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90077-4 · Cited by 105
Cyclosporin A Increases Nitric Oxide Activity In Vivo
Stroes, E. S. G., Lüscher, T. F., de Groot, F. G., Koomans, H. A., & Rabelink, T. J. (1997) · Hypertension · doi:10.1161/01.hyp.29.2.570 · Cited by 101
Bastenie, P. A. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90177-5 · Cited by 82
Monzani, F., Caraccio, N., Guerra, P. D., Casolaro, A., & Ferrannini, E. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00790.x · Cited by 78
Relationship between Thyroid Hormones and Plasma D-dimer Levels
Bruckert, É., Ankri, A., Beucler, I., Giral, P., Turpin, G., & Chadarévian, R. (1998) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614228 · Cited by 63
3,3',5'-Triiodothyronine inhibits collagen-induced human platelet aggregation
Masaki, H., Nishikawa, M., Urakami, M., Yoshimura, M., Toyoda, N., Mori, Y., YOSHIKAWA, N., & Inada, M. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.3.1517361 · Cited by 19
Maximal postischemic forearm vasodilation in human hypertension: a reassessment of the method
Pedrinelli, R., Taddei, S., Spessot, M., & Salvetti, A. (1987) · CINECA IRIS Institutial research information system (University of Pisa) · Cited by 9
Subclinical hypothyroidism: Neurobehavioural features and beneficial effect of L-thyroxine treatment
Monzani, F., Caraccio, N., Pucci, E., Baschieri, L., P, D. G., CA, P., & Luisi, M. (1993) · CINECA IRIS Institutial research information system (University of Pisa) · Cited by 8
Research works printed but not linked: 1
- Folkow, 1995, The structural factor in hypertension with special emphasis on the altered geometric design of the systemic arteries, In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and treatment. New York: Raven Press;, 481
Cited by
Sorted by citations
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber, K. A. (2012) · Endocrine Practice · doi:10.4158/ep12280.gl · Cited by 1,567
“5, indicating beneficial response in atherosclerosis risk factors such as atherogenic lipids (120–123), impaired endothelial function (124,125), and intima media thickness (126).”
The Clinical Significance of Subclinical Thyroid Dysfunction
Biondi, B., & Cooper, D. S. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0043 · Cited by 1,418
Klein, I., & Danzi, S. (2007) · Circulation · doi:10.1161/circulationaha.106.678326 · Cited by 1,324
Garber, J. R., Cobin, R. H., Gharib, H., Hennessey, J. V., Klein, I., Mechanick, J. I., Pessah-Pollack, R., Singer, P. A., & Woeber for the American Association, K. A. (2012) · Thyroid · doi:10.1089/thy.2012.0205 · Cited by 1,053
“A substantial number of studies have been done on patients with TSH levels between 2.5 and 4.5, indicating beneficial response in atherosclerosis risk factors such as atherogenic lipids (120–123), impaired endothelial function (124,125), and intima media thickness (126).”
InfluentialCooper, D. S., & Biondi, B. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60276-6 · Cited by 1,039
Metadata
- Authors
- Taddei, S., Caraccio, N., Virdis, A., Dardano, A., Versari, D., Ghiadoni, L., Salvetti, A., Ferrannini, E., & Monzani, F.
- Affiliations
- University of Pisa (IT)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-08-01
- Volume
- 88
- Issue
- 8
- Pages
- 3731-3737
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2060930755
- Cited by
- 431
- References
- 43
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 14 · 2023: 15 · 2022: 24 · 2021: 14 · 2020: 27 · 2019: 19 · 2018: 19 · 2017: 12 · 2016: 24 · 2015: 17 · 2014: 34 · 2013: 26 · 2012: 26
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- subclinical hypothyroidism, endothelial dysfunction, endothelium-dependent vasodilation, nitric oxide bioavailability, levothyroxine, acetylcholine, L-NMMA, forearm blood flow, dyslipidemia, cardiovascular risk, sodium nitroprusside
- MeSH terms
- Acetylcholine, Adult, Endothelium, Vascular, Enzyme Inhibitors, Female, Humans, Hypothyroidism, Iodide Peroxidase, Lipids, Lipoproteins, LDL, Male, Nitric Oxide, Nitroprusside, Regional Blood Flow, Thyroglobulin, Thyroid Hormones, Thyroiditis, Autoimmune, Thyroxine, Vascular Resistance, Vasodilation, Vasodilator Agents, Nitric Oxide Synthase, omega-N-Methylarginine, Nitric Oxide Donors, Nitric Oxide Synthase Type III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review